Cardiogenic shock treatment sales will expand through 2036, with devices holding 47.3% of the treatment type in 2026. The market was valued at USD 1.06 billion in 2025 and is expected to be worth USD 2.17 billion by 2036, creating an incremental opportunity of USD 1.07 billion between 2026 and 2036.